Authored By: Sarah
11 Jul 2024

 Central Nervous System (CNS) Stimulant Drugs Market Size to grow by USD 6486.71 million between 2023-2027

According to a research report “ Central Nervous System (CNS) Stimulant Drugs Market” by Distribution Channel (Hospitals, Others) Application (Attention-deficit hyperactivity disorder, Narcolepsy, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2027 published by Technavio, the market size is estimated to grow by USD 6486.71 million, at a CAGR of  5.8% during the forecast period. The global prevalence of Central Nervous System (CNS) disorders, including attention-deficit hyperactivity disorder (ADHD), sleep apnea, and narcolepsy, is on the rise, affecting a significant portion of the population, particularly children and adolescents. ADHD, a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity, has a global prevalence of 5.3%-5.9%, according to Le et al. (2021). In Europe alone, approximately 4.6% of children and adolescents are estimated to have ADHD. The OECD reports that annually, 1%-20% of European citizens are affected by ADHD. These statistics underscore the growing demand for Central Nervous System stimulant drugs to manage and treat these disorders.

Browse market data tables, figures, and in-depth TOC on “Central Nervous System (CNS) Stimulant Drugs Market” by Distribution Channel (Hospitals, Others) Application (Attention-deficit hyperactivity disorder, Narcolepsy, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2027. Download Free Sample

 

By Distribution Channel, the Hospitals segment is projected to dominate the market size in 2024

The hospital sector represents a significant market share in the Central Nervous System (CNS) stimulant drugs industry. Hospitals are primary consumers of these medications, primarily used to manage conditions such as Attention Deficit Hyperactivity Disorder (ADHD), narcolepsy, and sleep disorders. Additionally, CNS stimulant drugs are employed in hospitals to alleviate pain and enhance patient focus during surgical procedures. This application contributes to improved patient outcomes and reduced surgical complications. The hospital segment's demand for CNS stimulant drugs is projected to persist, given the ongoing need for these medications in healthcare settings.

By Application, Attention-deficit hyperactivity disorder  segment is expected to hold the largest market size for the year 2024

The Central Nervous System (CNS) stimulant drugs market is witnessing significant growth due to the increasing prevalence of Attention-Deficit Hyperactivity Disorder (ADHD), a chronic condition that impairs brain function or development. Stimulant therapy is the preferred treatment for managing ADHD symptoms, making it the first-line treatment for this condition. ADHD affects both children and adolescents globally, and the ease of access to these medications will fuel market expansion during the forecast period. The US Food and Drug Administration (FDA) has approved 29 stimulant drugs for treating ADHD in the US, including Adhansia XR, a CNS stimulant developed by Purdue Pharma. This approval underscores the market's potential and the ongoing research and development efforts in this space.

North America is forecasted to hold the largest market size by region in 2024

The Central Nervous System (CNS) stimulant drugs market in North America is experiencing significant growth, primarily driven by the increasing prevalence of neurological disorders such as Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD) in the US and Canada. According to recent statistics, in 2021, approximately 9.4% of children in the US aged 2-17 years were diagnosed with ADHD, while in Canada, 1.52% of children and youth aged 5-17 years were diagnosed with ASD. In Ontario alone, 5% of youth were diagnosed with ADHD. Among US states, Alabama had the highest number (9.1 million) of adolescents diagnosed with ADHD in 2021. These statistics underscore the substantial market potential for CNS stimulant drugs in North America.

The Central Nervous System (CNS) Stimulant Drugs Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Astellas Pharma Inc.
  • Azurity Pharmaceuticals Inc.
  • Elite Pharmaceuticals Inc.
  • Hisamitsu Pharmaceutical Co. Inc.
  • Ironshore
  • Jazz Pharmaceuticals Plc
  • KemPharm Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Purdue Pharma LP
  • Sanofi SA
  • Shionogi and Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Tris Pharma Inc.
  • Viatris Inc.
  • Thermo Fisher Scientific Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Central Nervous System (CNS) stimulant drugs market is witnessing a robust growth trajectory, driven by the increasing prevalence of various neurological and psychiatric disorders such as narcolepsy, sleep apnea, and attention deficit hyperactivity disorder (ADHD) in the senior population and children & adolescents. According to recent projections, the market is expected to reach significant value by 2027, growing at a CAGR of over 5% during the forecast period. The demand for CNS stimulant drugs is high in hospitals, clinics, and sleep care online platforms. The American Thoracic Society estimates that over 22 million Americans have sleep disorders, and a significant number of them are treated with CNS stimulants. Moreover, the increasing prevalence of ADHD, which is often treated with CNS stimulants, is also contributing to the market growth. The market is segmented by application areas, including sleep disorders, ADHD, and other neurological disorders. The sleep disorders segment is further segmented into narcolepsy, sleep apnea, and other sleep disorders. The increasing awareness and diagnosis of these disorders, coupled with the availability of effective treatments, are expected to drive the growth of the CNS stimulant drugs market in the coming years.

Market Research Overview

Title: Central Nervous System (CNS) Stimulant Drugs Market: Strategies, Priorities, Success Factors, and Growth Trajectory The Central Nervous System (CNS) stimulant drugs market is witnessing significant growth due to the increasing prevalence of neurological disorders such as narcolepsy, sleep apnea, and attention deficit hyperactivity disorder (ADHD). The market's current priorities include inorganic growth strategies like mergers and acquisitions, collaborations, and partnerships. Success factors include the development of innovative, cutting-edge CNS stimulant drugs that cater to specific patient needs. Financial details indicate that the market's value was estimated at USD14.3 billion in 2020 and is projected to reach USD21.3 billion by 2026, growing at a CAGR of 7.5% during the forecast period. Industry coverage includes key players like Independence Pharmaceuticals, Sleep Care Online, American Thoracic Society, and others. The senior population segment is a significant target due to the increasing prevalence of sleep disorders. Clinics and healthcare services are also key customers. Country-level analysis reveals that the US and Europe dominate the market due to the high prevalence of neurological disorders and advanced healthcare infrastructure. Narcolepsy, sleep apnea, and child & adolescent psychiatry are key indications driving market growth. In conclusion, the CNS stimulant drugs market is an active and growing industry, with a focus on innovation, collaboration, and catering to the specific needs of patients. Financial projections indicate significant growth, making it an attractive investment opportunity.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio